These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 37901702)

  • 1. Review of the Role of Rituximab in the Management of Adult Minimal Change Disease and Immune-Mediated Focal and Segmental Glomerulosclerosis.
    Aslam A; Koirala A
    Glomerular Dis; 2023; 3(1):211-219. PubMed ID: 37901702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial.
    Ravani P; Colucci M; Bruschi M; Vivarelli M; Cioni M; DiDonato A; Cravedi P; Lugani F; Antonini F; Prunotto M; Emma F; Angeletti A; Ghiggeri GM
    J Am Soc Nephrol; 2021 Oct; 32(10):2652-2663. PubMed ID: 34544820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab in Steroid-Dependent Podocytopathies.
    Costa C; Antunes A; Oliveira J; Pereira M; Godinho I; Fernandes P; Jorge S; Lopes JA; Gameiro J
    Glomerular Dis; 2024; 4(1):129-136. PubMed ID: 39144474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome.
    Sinha A; Bhatia D; Gulati A; Rawat M; Dinda AK; Hari P; Bagga A
    Nephrol Dial Transplant; 2015 Jan; 30(1):96-106. PubMed ID: 25121488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantibodies Targeting Nephrin in Podocytopathies.
    Hengel FE; Dehde S; Lassé M; Zahner G; Seifert L; Schnarre A; Kretz O; Demir F; Pinnschmidt HO; Grahammer F; Lucas R; Mehner LM; Zimmermann T; Billing AM; Oh J; Mitrotti A; Pontrelli P; Debiec H; Dossier C; Colucci M; Emma F; Smoyer WE; Weins A; Schaefer F; Alachkar N; Diemert A; Hogan J; Hoxha E; Wiech T; Rinschen MM; Ronco P; Vivarelli M; Gesualdo L; Tomas NM; Huber TB;
    N Engl J Med; 2024 Aug; 391(5):422-433. PubMed ID: 38804512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort.
    Trautmann A; Bodria M; Ozaltin F; Gheisari A; Melk A; Azocar M; Anarat A; Caliskan S; Emma F; Gellermann J; Oh J; Baskin E; Ksiazek J; Remuzzi G; Erdogan O; Akman S; Dusek J; Davitaia T; Özkaya O; Papachristou F; Firszt-Adamczyk A; Urasinski T; Testa S; Krmar RT; Hyla-Klekot L; Pasini A; Özcakar ZB; Sallay P; Cakar N; Galanti M; Terzic J; Aoun B; Caldas Afonso A; Szymanik-Grzelak H; Lipska BS; Schnaidt S; Schaefer F;
    Clin J Am Soc Nephrol; 2015 Apr; 10(4):592-600. PubMed ID: 25635037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children.
    Kamei K; Ishikura K; Sako M; Ito S; Nozu K; Iijima K
    Pediatr Nephrol; 2020 Jan; 35(1):17-24. PubMed ID: 30564879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy.
    Ramachandran R; Bharati J; Rao I; Kashif AW; Nada R; Minz R; Gupta KL; Kohli HS
    Nephrology (Carlton); 2019 Dec; 24(12):1241-1247. PubMed ID: 30586217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab in The Management of Pediatric Steroid-Resistant Nephrotic Syndrome: A Systematic Review.
    Jellouli M; Charfi R; Maalej B; Mahfoud A; Trabelsi S; Gargah T
    J Pediatr; 2018 Jun; 197():191-197.e1. PubMed ID: 29680473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remission of steroid-resistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab.
    Suri M; Tran K; Sharma AP; Filler G; Grimmer J
    Int Urol Nephrol; 2008; 40(3):807-10. PubMed ID: 18491215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome.
    Ruggenenti P; Ruggiero B; Cravedi P; Vivarelli M; Massella L; Marasà M; Chianca A; Rubis N; Ene-Iordache B; Rudnicki M; Pollastro RM; Capasso G; Pisani A; Pennesi M; Emma F; Remuzzi G;
    J Am Soc Nephrol; 2014 Apr; 25(4):850-63. PubMed ID: 24480824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases.
    Kronbichler A; König P; Busch M; Wolf G; Mayer G; Rudnicki M
    Wien Klin Wochenschr; 2013 Jun; 125(11-12):328-33. PubMed ID: 23624956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab experience in children with nephrotic syndrome: what have we observed differently.
    Girişgen İ; Yüksel S; Pekal Y
    Turk Pediatri Ars; 2020; 55(1):60-66. PubMed ID: 32231451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab in adult minimal change disease and focal segmental glomerulosclerosis.
    Kronbichler A; Bruchfeld A
    Nephron Clin Pract; 2014; 128(3-4):277-82. PubMed ID: 25401966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?
    Gauckler P; Shin JI; Alberici F; Audard V; Bruchfeld A; Busch M; Cheung CK; Crnogorac M; Delbarba E; Eller K; Faguer S; Galesic K; Griffin S; Hrušková Z; Jeyabalan A; Karras A; King C; Kohli HS; Maas R; Mayer G; Moiseev S; Muto M; Odler B; Pepper RJ; Quintana LF; Radhakrishnan J; Ramachandran R; Salama AD; Segelmark M; Tesař V; Wetzels J; Willcocks L; Windpessl M; Zand L; Zonozi R; Kronbichler A;
    Autoimmun Rev; 2020 Nov; 19(11):102671. PubMed ID: 32942039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous B-cell depletion in frequently relapsing, steroid-dependent and steroid-resistant nephrotic syndrome.
    Cortazar FB; Rosenthal J; Laliberte K; Niles JL
    Clin Kidney J; 2019 Apr; 12(2):224-231. PubMed ID: 30976400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Difficult-to-treat idiopathic nephrotic syndrome: established drugs, open questions and future options.
    Kemper MJ; Valentin L; van Husen M
    Pediatr Nephrol; 2018 Oct; 33(10):1641-1649. PubMed ID: 28879428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab, Mycophenolic Acid, and Calcineurin Inhibitors Achieve Long-Term Remission in Pediatric Focal Segmental Glomerulosclerosis with Steroid-Resistant and Frequently Relapsing Nephrotic Syndrome: A Report of Two Cases.
    Ambarsari CG; Saraswati M; Laudza GS
    Case Rep Nephrol Dial; 2022; 12(3):167-177. PubMed ID: 36518356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children.
    Ravani P; Bonanni A; Rossi R; Caridi G; Ghiggeri GM
    Clin J Am Soc Nephrol; 2016 Apr; 11(4):710-20. PubMed ID: 26585985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis.
    Xue C; Yang B; Xu J; Zhou C; Zhang L; Gao X; Dai B; Yu S; Mao Z; Mei C; Xu C
    Clin Kidney J; 2021 Apr; 14(4):1042-1054. PubMed ID: 34094516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.